PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

PR Newswire

prCenter

6h ago

Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancertranslating…

B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that…

Factuality

70/100

Political Bias

Center

Ownership

Cision

Country

USA

Region

North America

Language

English

Keywords#ARTEMIS-008 Trial#III ARTEMIS-008#Phase III#Survival#ARTEMIS-008 Trial Shows

Read Original ↗

Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer | Pulse Aggregator